Ascendis Pharma A (ASND) Total Non-Current Liabilities (2019 - 2026)

Ascendis Pharma A (ASND) has 8 years of Total Non-Current Liabilities data on file, last reported at $454.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 18.24% year-over-year to $454.9 million; the trailing twelve-month figure through Mar 2026 stood at $454.9 million (up 18.24% YoY), and the FY2025 full-year result was $461.0 million, up 16.66% from the prior year.
• Total Non-Current Liabilities declined to $454.9 million in Q1 2026, from $461.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $798.9 million in Q3 2023 to a low of $249.5 million in Q2 2024.
• A 5-year average of $492.4 million and a median of $454.9 million in 2026 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities soared 532.72% in 2022 and sank 62.21% in 2023, its largest moves.
• Tracing ASND's Total Non-Current Liabilities over 5 years: stood at $668.4 million in 2022, then sank by 62.21% to $252.6 million in 2023, then soared by 54.44% to $390.1 million in 2024, then gained by 18.16% to $461.0 million in 2025, then slipped by 1.32% to $454.9 million in 2026.
• Business Quant data shows ASND's Total Non-Current Liabilities at $454.9 million in Q1 2026, $461.0 million in Q4 2025, and $400.2 million in Q3 2025.